<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513940</url>
  </required_header>
  <id_info>
    <org_study_id>1507526854</org_study_id>
    <nct_id>NCT02513940</nct_id>
  </id_info>
  <brief_title>Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes</brief_title>
  <official_title>Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with
      corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the
      US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in
      women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for
      drug-induced TdP in men, possibly due to declining serum testosterone concentrations.
      Available evidence shows an inverse relationship between QTc intervals and serum testosterone
      concentrations. In addition, experimental data, including those from the investigators'
      laboratory, suggest that both exogenous testosterone or progesterone administration may be
      protective against prolongation of ventricular repolarization and TdP. Specific Aim:
      Establish the influence of transdermal testosterone administration and oral progesterone
      administration as preventive methods by which to diminish the degree of drug-induced QT
      interval prolongation in men 65 years of age or older. Hypothesis: Transdermal testosterone
      administration and oral progesterone administration both effectively attenuate drug-induced
      QT interval response in older men. To test this hypothesis, transdermal testosterone, oral
      progesterone or placebo will be administered in a 3-way crossover study to men 65 years of
      age or older. QTc interval response to low-dose ibutilide will be assessed. The primary
      endpoints will be individually-corrected QT interval (QTcI) response to ibutilide, in the
      presence and absence of testosterone, and in the presence or absence of progesterone: 1)
      Effect on pre-ibutilide QTcI, 2) Effect on maximum post-ibutilide QTcI, 3) Effect on % change
      in post-ibutilide QTcI, and 2) Area under the QTcI interval-time curves.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline (pre-ibutilide) individualized rate-corrected QT interval (QTcI)</measure>
    <time_frame>Following 7 days of testosterone, progesterone or placebo</time_frame>
    <description>Testosterone/progesterone/placebo will be administered for 7 days - on last day, ibutilide will be administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum QTcI following ibutilide 0.003 mg/kg</measure>
    <time_frame>Within 8 hours following ibutilide administration</time_frame>
    <description>Testosterone/progesterone/placebo will be administered for 7 days - on last day, ibutilide will be administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum % change from pretreatment value in QTcI following ibutilide 0.003 mg/kg</measure>
    <time_frame>Within 8 hours of ibutilide administration</time_frame>
    <description>Testosterone/progesterone/placebo will be administered for 7 days - on last day, ibutilide will be administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the QTcI versus time curve for 0-1 hour following ibutilide 0.003 mg/kg</measure>
    <time_frame>1 hour following ibutilide administration</time_frame>
    <description>Testosterone/progesterone/placebo will be administered for 7 days - on last day, ibutilide will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects associated with testosterone, progesterone and placebo</measure>
    <time_frame>During 7 day administration periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prolonged QT Interval in EKG and Sudden Death</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone gel 1% 100 mg daily x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone 400 mg orally daily x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dual matching placebo capsules and placebo topical gel every day x 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days</description>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Subjects will receive transdermal placebo gel every evening and oral placebo two capsules once daily for 7 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval</description>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corvert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men â‰¥ 65 years of age

        Exclusion Criteria:

          -  Prostate cancer; history of prostate cancer;

          -  History of breast cancer; benign prostatic hypertrophy;

          -  Weight &lt; 60 kg

          -  Weight &gt; 135 kg

          -  Serum k+ &lt; 3.6 mEq/L;

          -  Serum mg2+ &lt; 1.8 mg/dL;

          -  Hemoglobin &lt; 9.0 mg/dL;

          -  Hematocrit &lt; 26%;

          -  Hepatic transaminases &gt; 3x upper limit of normal;

          -  Baseline Bazett's-corrected QT interval &gt; 450 ms

          -  Heart failure due to reduced ejection fraction (left ventricular ejection fraction &lt;
             40%)

          -  Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death;

          -  Concomitant use of any QT interval-prolonging drug.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>James E. Tisdale</investigator_full_name>
    <investigator_title>Adjunct Professor</investigator_title>
  </responsible_party>
  <keyword>Torsades de pointes</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Risk reduction</keyword>
  <keyword>Electrocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden</mesh_term>
    <mesh_term>Torsades de Pointes</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Jervell-Lange Nielsen Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Ibutilide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

